CVS Health launches new brand Cordavis to target $100 billion biosimilar market

CVS Health has launched a new business unit called Cordavis to bring private label biosimilar drugs to the market, aiming to reduce drug costs and have a share in the projected $100 billion market by 2029. Cordavis will co-manufacture and commercialize biosimilars, starting with Sandoz's Hymiroz at 80% less than AbbVie's Humira, and CVS plans to select products with adequate supply to avoid shortages in the specialty drug market.

yahoo.com

Relevant topic timeline:

8/23/2023

CVS pushes into making cheaper versions of complex drugs with new discount Humira

CVS Health is partnering with Sandoz to produce a cheaper version of the arthritis drug Humira, as part of its venture into the biosimilars market.

8/26/2023

CVS Joins Race to Sell Cheaper, 'Biosimilar' Drugs

CVS will begin selling cheaper biosimilar versions of prescription medications, starting with its own version of Humira, aiming to drive down the cost of biologic drugs and encourage investment in them.